Aptevo Therapeutics (APVO) Projected to Announce Earnings on Thursday

Aptevo Therapeutics (NASDAQ:APVO) is expected to release its results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($3.72) per share for the quarter.

Aptevo Therapeutics (NASDAQ:APVO) last announced its earnings results on Friday, August 14th. The biotechnology company reported ($5.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($6.02) by $0.71. On average, analysts expect Aptevo Therapeutics to post ($17.04) EPS for the current fiscal year and ($6.59) EPS for the next fiscal year.

Aptevo Therapeutics Stock Up 1.6%

NASDAQ:APVO opened at $1.30 on Thursday. Aptevo Therapeutics has a 1-year low of $1.25 and a 1-year high of $28.44. The firm has a market capitalization of $2.35 million, a price-to-earnings ratio of -0.03 and a beta of 1.67. The stock has a fifty day simple moving average of $1.91 and a 200 day simple moving average of $4.49.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Aptevo Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, October 14th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, Aptevo Therapeutics currently has an average rating of “Sell”.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc is a biotechnology company developing targeted immunotherapies for cancer and other serious diseases. The company is headquartered in Seattle, Washington, and was established in 2016 as a spin-off from Emergent BioSolutions.

Aptevo’s research is based primarily on its ADAPTIR and ADAPTIR-FLEX antibody platforms, which are designed to create bispecific immune-cell engagers. These therapies are intended to connect immune cells with cancer cells or activate immune pathways to produce a targeted response.